Compare Cytokinetics Inc (CYTK) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Walmart Stores Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Walmart Stores Inc trades at $110.41 (market cap $877.15B). The key difference: Walmart Stores Inc is far larger — about 101.8× Cytokinetics Inc's market cap, and Walmart Stores Inc pays a 0.9% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Walmart Stores Inc for 101 Days on average.
| CYTK | WMT | |
|---|---|---|
Market Cap | $8.62B | $877.15B |
Volume | 2,594,626 | 23,616,578 |
Sector | Health | Consumer Staples |
52-Week High | $87.26 | $134.20 |
52-Week Low | $54.76 | $100.61 |
Typical Hold Time | 19 Days | 101 Days |
Enterprise Value | $8.72B | $939.38B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Walmart (WMT) trades at $108.11, up 0.82% today, with a neutral technical signal and strong fundamentals. Revenue grew to $681.0B in 2025, with net income rising to $19.4B and a 2.85% margin. The company has beaten EPS estimates for three consecutive quarters, and analyst consensus is a Buy with a $128.84 price target. Recent news highlights expansion in AI, e-commerce, and Medicare Advantage plans, supporting market share gains.
The outlook is positive due to consistent earnings beats, digital growth, and strategic initiatives, but risks include high valuation (P/E 40.06), rising costs, and economic sensitivity. Upside potential exists toward the consensus target, though near-term volatility may persist amid inflation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
